• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.推动骨髓增生异常综合征研究的议程：来自骨髓增生异常综合征首次国际研讨会的十大优先事项清单
Blood Adv. 2023 Jun 27;7(12):2709-2714. doi: 10.1182/bloodadvances.2022008747.
2
[Molecular international prognostic scoring system for myelodysplastic syndromes].[骨髓增生异常综合征的分子国际预后评分系统]
Rinsho Ketsueki. 2023;64(5):355-368. doi: 10.11406/rinketsu.64.355.
3
Pediatric myelodysplastic syndromes.小儿骨髓增生异常综合征
Curr Treat Options Oncol. 2005 May;6(3):209-14. doi: 10.1007/s11864-005-0004-3.
4
[Myelodysplastic syndromes (MDS)].骨髓增生异常综合征（MDS）
Dtsch Med Wochenschr. 2012 Feb;137(5):183-5. doi: 10.1055/s-0031-1292887. Epub 2012 Jan 25.
5
Myelodysplastic syndromes.骨髓增生异常综合征
Ann N Y Acad Sci. 2004 Dec;1028:400-8. doi: 10.1196/annals.1322.048.
6
Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop.骨髓增生异常综合征 (MDS) 患者的诊断和预后评估进展更新：专家研讨会的共识声明和报告。
Leuk Res. 2012 Mar;36(3):264-70. doi: 10.1016/j.leukres.2011.11.005. Epub 2011 Dec 3.
7
The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.骨髓增生异常综合征的遗传学：经典细胞遗传学与近期分子见解
Hematology. 2006 Feb;11(1):1-13. doi: 10.1080/10245330500276691.
8
Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop.治疗相关骨髓增生异常综合征和急性髓系白血病中的独特平衡染色体异常：来自一个国际研讨会的报告
Genes Chromosomes Cancer. 2002 Apr;33(4):413-23. doi: 10.1002/gcc.10045.
9
Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.
Semin Hematol. 2004 Apr;41(2 Suppl 4):6-12. doi: 10.1053/j.seminhematol.2004.02.002.
10
Treatment strategies in myelodysplastic syndromes.骨髓增生异常综合征的治疗策略
Cancer Invest. 2008 Mar;26(2):208-16. doi: 10.1080/07357900701788122.

引用本文的文献

1
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.在新诊断的高危骨髓增生异常综合征中，他米巴罗汀联合阿扎胞苷的SELECT-MDS-1 3期研究的关键结果。
Blood Adv. 2025 Aug 26;9(16):4090-4099. doi: 10.1182/bloodadvances.2025016229.
2
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.关于髓系肿瘤和急性白血病分类的实用方法：WHO 和 ICC。
J Hematol Oncol. 2024 Jul 29;17(1):56. doi: 10.1186/s13045-024-01571-4.
3
cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory.克隆率：利用合并理论快速估计单细胞克隆动态。
Bioinformatics. 2023 Sep 2;39(9). doi: 10.1093/bioinformatics/btad561.

本文引用的文献

1
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).评估骨髓增生异常综合征（MDS）中部分血液学恢复（CRh）作为完全缓解（CR）的反应标准。
Blood Cancer J. 2022 Nov 15;12(11):153. doi: 10.1038/s41408-022-00748-9.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
4
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
5
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.培尼达司他联合阿扎胞苷对比阿扎胞苷单药治疗高危骨髓增生异常综合征/慢性粒单核细胞白血病或低比例骨髓原始细胞急性髓系白血病。
Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334.
6
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.突变型 TP53 急性髓系白血病和高危骨髓增生异常综合征的分子特征。
Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472.
7
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?高危骨髓增生异常综合征中低甲基化剂治疗的真实世界应用和结局：我们为何未能实现临床试验的承诺？
Future Oncol. 2021 Dec;17(36):5163-5175. doi: 10.2217/fon-2021-0936. Epub 2021 Oct 12.
8
Relationship between clone metrics and clinical outcome in clonal cytopenia.克隆性血细胞减少症中克隆指标与临床结局的关系。
Blood. 2021 Sep 16;138(11):965-976. doi: 10.1182/blood.2021011323.
9
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.从 MDS 中区分 AML：固定的 blast 百分比可能不再是最佳选择。
Blood. 2022 Jan 20;139(3):323-332. doi: 10.1182/blood.2021011304.
10
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.不完全反应的完整故事：急性髓系白血病临床反应的演变和应用。
Blood Rev. 2021 Jul;48:100806. doi: 10.1016/j.blre.2021.100806. Epub 2021 Jan 29.

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.

作者信息

Stahl Maximilian, Abdel-Wahab Omar, Wei Andrew H, Savona Michael R, Xu Mina L, Xie Zhuoer, Taylor Justin, Starczynowski Daniel, Sanz Guillermo F, Sallman David A, Santini Valeria, Roboz Gail J, Patnaik Mrinal M, Padron Eric, Odenike Olatoyosi, Nazha Aziz, Nimer Stephen D, Majeti Ravindra, Little Richard F, Gore Steven, List Alan F, Kutchroo Vijay, Komrokji Rami S, Kim Tae Kon, Kim Nina, Hourigan Christopher S, Hasserjian Robert P, Halene Stephanie, Griffiths Elizabeth A, Greenberg Peter L, Figueroa Maria, Fenaux Pierre, Efficace Fabio, DeZern Amy E, Della Porta Matteo G, Daver Naval G, Churpek Jane E, Carraway Hetty E, Brunner Andrew M, Borate Uma, Bennett John M, Bejar Rafael, Boultwood Jacqueline, Loghavi Sanam, Bewersdorf Jan Philipp, Platzbecker Uwe, Steensma David P, Sekeres Mikkael A, Buckstein Rena J, Zeidan Amer M

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Blood Adv. 2023 Jun 27;7(12):2709-2714. doi: 10.1182/bloodadvances.2022008747.

DOI:10.1182/bloodadvances.2022008747
PMID:36260702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10333740/
Abstract
摘要